PATENT CLAIM ANALYSIS

Application Number: 15882724
Application Type: Utility
Filing Date: 2018-01
Publication Date: 2018-06
Patent Classification: ["424", "093210"]

Abstract:
The present disclosure relates to nucleic acid vaccine compositions and methods for preventing or treating pathological conditions, such as cancer or infectious disease. Further, the disclosure provides methods for more efficient production of antigens via mRNA containing one or more non-conventional start codons to promote multiplex initiation of translation in eukaryotic cells.

Claim (Index 1):
A method of eliciting an immune response, comprising administering to a human subject an effective amount of a population of immune cells comprising immune cells containing a chimeric nucleic acid molecule,\n wherein the chimeric nucleic acid molecule comprises a multiplex translation initiation (MTI) sequence comprising from two to about five translation initiation sites operatively linked in frame to a nucleic acid molecule encoding a fusion protein comprised of a plurality of antigenic peptides, wherein at least one of the MTI translation initiation sites is a non-AUG translation initiation site and the MTI allows the production of more than one mole of fusion protein per mole of mRNA, thereby eliciting an immune response.

Metadata:
- Claim Count in Document: 80.0
- Percentile: 86.0
- Lexical Diversity: 1.21739
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15222619', '15180852', '15222627', '14660924', '10343448']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8325306538544514
- 35 USC 102 Novelty (BERT): 0.681287239839897
- Combined Prediction Score: 0.817406312452996
- Mean Citation Score: 666.5319900000002
- Max Citation Score: 761.4291400000003
- Similarity Product: 674.0831728793812

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test